Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Dulaglutide
Drug: Placebo
Drug: SGLT2 inhibitor
Drug: Metformin

First Posted Date: 2015-11-04

Last Posted Date: 2020-06-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 424

Registration Number: NCT02597049

Locations: 🇵🇷
Manati Medical Center, Manati, Puerto Rico
🇺🇸
Grand Street Medical PC, Brooklyn, New York, United States
🇺🇸
PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States

and more 14 locations

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: LY3127804
Drug: Ramucirumab
Drug: Paclitaxel

First Posted Date: 2015-11-04

Last Posted Date: 2020-10-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 105

Registration Number: NCT02597036

Locations: 🇺🇸
SMO Sarah Cannon Research Inst., Nashville, Tennessee, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain

A Study of LY3200327 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo (SC)
Drug: LY3200327 (SC)
Drug: LY3200327 (IV)
Drug: Placebo (IV)

First Posted Date: 2015-11-03

Last Posted Date: 2016-09-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 52

Registration Number: NCT02595736

Locations: 🇺🇸
Parexel International/ California Clinical Trials, Glendale, California, United States

A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

Phase 1

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: U-500R

First Posted Date: 2015-10-28

Last Posted Date: 2023-10-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 11

Registration Number: NCT02588950

Locations: 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Mirikizumab

First Posted Date: 2015-10-28

Last Posted Date: 2020-06-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 249

Registration Number: NCT02589665

Locations: 🇺🇸
Minnesota Gastroenterology, P.A., Plymouth, Minnesota, United States
🇺🇸
Carolinas Healthcare System, Charlotte, North Carolina, United States
🇺🇸
Borland Groover Clinic, Jacksonville, Florida, United States

and more 11 locations

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Ixekizumab
Drug: Placebo

First Posted Date: 2015-10-23

Last Posted Date: 2019-11-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 394

Registration Number: NCT02584855

Locations: 🇺🇸
Heartland Research Associates, Wichita, Kansas, United States
🇺🇸
University of California, Davis - Health Systems, Sacramento, California, United States
🇺🇸
Robert A. Harrell, III, MD, Durham, North Carolina, United States

and more 19 locations

A Study of [¹⁴C]-LY3023414 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [¹⁴C]-LY3023414

First Posted Date: 2015-10-15

Last Posted Date: 2015-11-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 8

Registration Number: NCT02575703

Locations: 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States

A Study of Galcanezumab in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Galcanezumab
Drug: Placebo

First Posted Date: 2015-10-15

Last Posted Date: 2019-02-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 178

Registration Number: NCT02576951

Locations: 🇺🇸
Covance, Dallas, Texas, United States

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Baricitinib
Drug: Triamcinolone (Optional)

First Posted Date: 2015-10-15

Last Posted Date: 2020-06-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 124

Registration Number: NCT02576938

Locations: 🇺🇸
Medical Dermatology Specialists, Atlanta, Georgia, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Menter Dermatology Research Institute, Dallas, Texas, United States

and more 7 locations

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Phase 1

Completed

Conditions: Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Non-Small Cell Lung Cancer
Hepatocellular Carcinoma

Interventions: Drug: Ramucirumab
Drug: MEDI4736

First Posted Date: 2015-10-09

Last Posted Date: 2021-01-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 85

Registration Number: NCT02572687

Locations: 🇺🇸
UCLA Medical Center, Santa Monica, California, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Washington University Medical Center, Saint Louis, Missouri, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy